Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthias Augustin

Showing results (471-480 of 491) with videos related to

Pageof 50
Sort By:
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|October 8, 2021
Documentation of psoriasis in routine care - expert consensus on a German data setMarina Otten, Ulrich Mrowietz, Ralph Michael von Kiedrowski, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|July 11, 2007
Evidence-based (S3) guidelines for the treatment of psoriasis vulgarisAlexander Nast, Ina B Kopp, Matthias Augustin, et al.
Allergy|April 9, 2023
Dupilumab but not cyclosporine treatment shifts the microbiome toward a healthy skin flora in patients with moderate-to-severe atopic dermatitisJan Hartmann, Lucas Moitinho-Silva, Nicole Sander, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|October 13, 2025
Safety and efficacy of nemolizumab for atopic dermatitis up to 2 years in open-label extension studyMatthias Augustin, Marie Tauber, Robert Sidbury, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|October 19, 2022
Quality of life measurement in vitiligo. Position statement of the European Academy of Dermatology and Venereology Task Force on Quality of Life and Patient Oriented Outcomes with external expertsPavel V Chernyshov, Lucia Tomas-Aragones, Liana Manolache, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|February 5, 2026
S3 Guideline for the Treatment of Psoriasis vulgaris, adapted from EuroGuiDerm - part 2: Specific clinical and comorbid situationsAlexander Nast, Andreas Altenburg, Matthias Augustin, et al.
JAMA Dermatology|November 27, 2024
Efficacy and Safety of Nemolizumab in Patients With Moderate to Severe Prurigo Nodularis: The OLYMPIA 1 Randomized Clinical Phase 3 TrialSonja Ständer, Gil Yosipovitch, Franz J Legat, et al.
Acta Dermato-Venereologica|December 15, 2020
Chronic Nodular Prurigo: A European Cross-sectional Study of Patient Perspectives on Therapeutic Goals and SatisfactionManuel P Pereira, Claudia Zeidler, Joanna Wallengren, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|April 25, 2024
Obesity is linked to disease severity in moderate to severe atopic dermatitis-Data from the prospective observational TREATgermany registryStephan Traidl, Moritz M Hollstein, Nadine Kroeger, et al.
International Journal of Dermatology|May 18, 2026
Position Statement of the EADV Task Forces With External Experts on Quality of Life Measurement in Hidradenitis Suppurativa: An UpdatePavel V Chernyshov, Gregor Jemec, Andrew Finlay, et al.
Pageof 50

Showing results (471-480 of 491) with videos related to

Sort By:
Pageof 50
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|October 8, 2021
Documentation of psoriasis in routine care - expert consensus on a German data setMarina Otten, Ulrich Mrowietz, Ralph Michael von Kiedrowski, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|July 11, 2007
Evidence-based (S3) guidelines for the treatment of psoriasis vulgarisAlexander Nast, Ina B Kopp, Matthias Augustin, et al.
Allergy|April 9, 2023
Dupilumab but not cyclosporine treatment shifts the microbiome toward a healthy skin flora in patients with moderate-to-severe atopic dermatitisJan Hartmann, Lucas Moitinho-Silva, Nicole Sander, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|October 13, 2025
Safety and efficacy of nemolizumab for atopic dermatitis up to 2 years in open-label extension studyMatthias Augustin, Marie Tauber, Robert Sidbury, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|October 19, 2022
Quality of life measurement in vitiligo. Position statement of the European Academy of Dermatology and Venereology Task Force on Quality of Life and Patient Oriented Outcomes with external expertsPavel V Chernyshov, Lucia Tomas-Aragones, Liana Manolache, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|February 5, 2026
S3 Guideline for the Treatment of Psoriasis vulgaris, adapted from EuroGuiDerm - part 2: Specific clinical and comorbid situationsAlexander Nast, Andreas Altenburg, Matthias Augustin, et al.
JAMA Dermatology|November 27, 2024
Efficacy and Safety of Nemolizumab in Patients With Moderate to Severe Prurigo Nodularis: The OLYMPIA 1 Randomized Clinical Phase 3 TrialSonja Ständer, Gil Yosipovitch, Franz J Legat, et al.
Acta Dermato-Venereologica|December 15, 2020
Chronic Nodular Prurigo: A European Cross-sectional Study of Patient Perspectives on Therapeutic Goals and SatisfactionManuel P Pereira, Claudia Zeidler, Joanna Wallengren, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|April 25, 2024
Obesity is linked to disease severity in moderate to severe atopic dermatitis-Data from the prospective observational TREATgermany registryStephan Traidl, Moritz M Hollstein, Nadine Kroeger, et al.
International Journal of Dermatology|May 18, 2026
Position Statement of the EADV Task Forces With External Experts on Quality of Life Measurement in Hidradenitis Suppurativa: An UpdatePavel V Chernyshov, Gregor Jemec, Andrew Finlay, et al.
Pageof 50